EntryPoint Capital’s Rocket Pharmaceuticals RCKT Stock Holding History

EntryPoint Capital’s Portfolio RCKT Stock Details RCKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-96,354	Closed	-$338K	–	887
2025 Q4	$338K	Sell	96,354 -29,236	-23%	-$100K	0.13%	310
2025 Q3	$409K	Sell	125,590 -175,463	-58%	-$553K	0.16%	235
2025 Q2	$738K	Buy	301,053 +224,634	+294%	+$1.14M	0.37%	21
2025 Q1	$510K	Buy	76,419 +51,516	+207%	+$509K	0.23%	100
2024 Q4	$313K	Buy	+24,903	New	+$375K	0.13%	345

Other funds holding RCKT

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

EntryPoint Capital's RCKT Position: Q1 2026 in Review

EntryPoint Capital sold out of Rocket Pharmaceuticals (RCKT) in Q1 2026, closing a stake of 96,354 shares — an estimated $338K sold.

EntryPoint Capital first reported a position in RCKT in Q4 2024 and held it in 5 quarters. The position peaked at $738K in Q2 2025. 199 funds tracked by Wall St. Rank hold RCKT as of Q1 2026.

EntryPoint Capital reported no remaining Rocket Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
EntryPoint Capital sold 96,354 Rocket Pharmaceuticals shares in Q1 2026, an estimated $338K.
EntryPoint Capital first reported a position in Rocket Pharmaceuticals in Q4 2024 and held it in 5 quarters.
EntryPoint Capital's Rocket Pharmaceuticals position peaked at $738K in Q2 2025.
199 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q1 2026.

Based on EntryPoint Capital's 13F filing for Q1 2026, filed 14 May 2026.